Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. / Nelson, Laerke M; Penninga, Luit; Sander, Kaare; Hansen, Peter B; Villadsen, Gerda Elisabeth; Rasmussen, Allan; Gustafsson, Finn.

I: Clinical Transplantation, 2013.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Nelson, LM, Penninga, L, Sander, K, Hansen, PB, Villadsen, GE, Rasmussen, A & Gustafsson, F 2013, 'Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy', Clinical Transplantation. https://doi.org/10.1111/ctr.12053

APA

Nelson, L. M., Penninga, L., Sander, K., Hansen, P. B., Villadsen, G. E., Rasmussen, A., & Gustafsson, F. (2013). Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clinical Transplantation. https://doi.org/10.1111/ctr.12053

Vancouver

Nelson LM, Penninga L, Sander K, Hansen PB, Villadsen GE, Rasmussen A o.a. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clinical Transplantation. 2013. https://doi.org/10.1111/ctr.12053

Author

Nelson, Laerke M ; Penninga, Luit ; Sander, Kaare ; Hansen, Peter B ; Villadsen, Gerda Elisabeth ; Rasmussen, Allan ; Gustafsson, Finn. / Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. I: Clinical Transplantation. 2013.

Bibtex

@article{7611f2d731bd47509e84c83d9859fe7b,
title = "Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy",
abstract = "BACKGROUND: The amyloidogenic transthyretin (ATTR) mutation Leu111Met causes a primarily cardiac amyloidosis: Familial amyloidotic cardiomyopathy (FAC). Combined heart-liver transplantation (CHLTx) is the preferred treatment for patients with heart failure due to familial amyloidosis, but information on outcome of patients with Leu111Met mutation is limited. The aim of this study was to evaluate the long-term outcome of CHLTx in patients with FAC. METHODS AND MATERIALS: Between 1998 and 2009, CHLTx was performed in 7 FAC patients (four men). Six patients underwent simultaneous transplantation. All patients suffered from severe cardiomyopathy. RESULTS: Mean recipient age at transplantation was 48.3 ± 4.2 yr. Mean follow-up was 55 months. No peroperative mortality occured. Two patients died within the first year (infection, multi-organ failure) of transplantation. Cumulative survival at 4.5 yr was 71%. No significant liver rejections occurred. One patient experienced an episode of cardiac rejection requiring treatment (H2R). For the surviving five patients, most recent left ventricular ejection fraction was 0.61 ± 0.02, and plasma creatinine was 129 ± 47 μM. None developed significant allograft vasculopathy or neuropathy after transplantation. No recurrence of cardiac amyloid was found. CONCLUSIONS: CHLTx in selected patients with FAC due to Leu111Met mutation offers acceptable long-term survival, almost comparable with isolated cardiac transplantation. Allograft rejection was rare.",
author = "Nelson, {Laerke M} and Luit Penninga and Kaare Sander and Hansen, {Peter B} and Villadsen, {Gerda Elisabeth} and Allan Rasmussen and Finn Gustafsson",
note = "{\textcopyright} 2012 John Wiley & Sons A/S.",
year = "2013",
doi = "10.1111/ctr.12053",
language = "English",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy

AU - Nelson, Laerke M

AU - Penninga, Luit

AU - Sander, Kaare

AU - Hansen, Peter B

AU - Villadsen, Gerda Elisabeth

AU - Rasmussen, Allan

AU - Gustafsson, Finn

N1 - © 2012 John Wiley & Sons A/S.

PY - 2013

Y1 - 2013

N2 - BACKGROUND: The amyloidogenic transthyretin (ATTR) mutation Leu111Met causes a primarily cardiac amyloidosis: Familial amyloidotic cardiomyopathy (FAC). Combined heart-liver transplantation (CHLTx) is the preferred treatment for patients with heart failure due to familial amyloidosis, but information on outcome of patients with Leu111Met mutation is limited. The aim of this study was to evaluate the long-term outcome of CHLTx in patients with FAC. METHODS AND MATERIALS: Between 1998 and 2009, CHLTx was performed in 7 FAC patients (four men). Six patients underwent simultaneous transplantation. All patients suffered from severe cardiomyopathy. RESULTS: Mean recipient age at transplantation was 48.3 ± 4.2 yr. Mean follow-up was 55 months. No peroperative mortality occured. Two patients died within the first year (infection, multi-organ failure) of transplantation. Cumulative survival at 4.5 yr was 71%. No significant liver rejections occurred. One patient experienced an episode of cardiac rejection requiring treatment (H2R). For the surviving five patients, most recent left ventricular ejection fraction was 0.61 ± 0.02, and plasma creatinine was 129 ± 47 μM. None developed significant allograft vasculopathy or neuropathy after transplantation. No recurrence of cardiac amyloid was found. CONCLUSIONS: CHLTx in selected patients with FAC due to Leu111Met mutation offers acceptable long-term survival, almost comparable with isolated cardiac transplantation. Allograft rejection was rare.

AB - BACKGROUND: The amyloidogenic transthyretin (ATTR) mutation Leu111Met causes a primarily cardiac amyloidosis: Familial amyloidotic cardiomyopathy (FAC). Combined heart-liver transplantation (CHLTx) is the preferred treatment for patients with heart failure due to familial amyloidosis, but information on outcome of patients with Leu111Met mutation is limited. The aim of this study was to evaluate the long-term outcome of CHLTx in patients with FAC. METHODS AND MATERIALS: Between 1998 and 2009, CHLTx was performed in 7 FAC patients (four men). Six patients underwent simultaneous transplantation. All patients suffered from severe cardiomyopathy. RESULTS: Mean recipient age at transplantation was 48.3 ± 4.2 yr. Mean follow-up was 55 months. No peroperative mortality occured. Two patients died within the first year (infection, multi-organ failure) of transplantation. Cumulative survival at 4.5 yr was 71%. No significant liver rejections occurred. One patient experienced an episode of cardiac rejection requiring treatment (H2R). For the surviving five patients, most recent left ventricular ejection fraction was 0.61 ± 0.02, and plasma creatinine was 129 ± 47 μM. None developed significant allograft vasculopathy or neuropathy after transplantation. No recurrence of cardiac amyloid was found. CONCLUSIONS: CHLTx in selected patients with FAC due to Leu111Met mutation offers acceptable long-term survival, almost comparable with isolated cardiac transplantation. Allograft rejection was rare.

U2 - 10.1111/ctr.12053

DO - 10.1111/ctr.12053

M3 - Journal article

C2 - 23278526

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

ER -

ID: 48457901